These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://harleyissx586153.blog-mall.com/39814739/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide